A previous study demonstrated that metformin combined with hypoglycemia impaired tumor metabolic plasticity and growth by modulating the Protein phosphatase 2A (PP2A)-glycogen synthase kinase 3beta (GSK3β)-myeloid cell leukemia 1 (MCL-1) axis [40]. Here, MCL1 is linked to neoplasm.